Niagen Bioscience Inc (NAGE) — Smart Money Tracker (13F, Q2 2026)

NAGE ranks #3829 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

141 institutions disclose a position in NAGE, but none treat it as a major bet — even Tieton Capital Management, LLC, its most concentrated holder, allocates just 1.8% of its own portfolio to it.

SteelPeak Wealth, LLC has trimmed its NAGE position for two straight quarters, cutting it by $4.4M while still holding $10.4M.

NAGE is up 2% today, but institutions show net selling of $10.1M this quarter — a divergence between today's price move and the underlying institutional flow.

NAGE posted net income of $16.0M over the trailing twelve months, and currently trades at a P/E of 13.8.

• Profitable — net income of $16.0M over the trailing twelve months
• Revenue grew 11.0% year over year
• Net income declined year over year, from $17.7M to $16.0M
• Generated $13.5M in positive operating cash flow
• Current ratio of 4.86x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.39x equity — within a conventional range